Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms

PLoS Computational Biology

Volumn 11, Issue 1, 2015, Pages

  Mahoney, J Matthew ^a   Taroni, Jaclyn ^a   Martyanov, Viktor ^a   Wood, Tammara A ^a   Greene, Casey S ^a   Pioli, Patricia A ^a   Hinchcliff, Monique E ^b   Whitfield, Michael L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPSY; CELL PROLIFERATION; CLUSTER ANALYSIS; INFORMATION THEORY; SET THEORY;

AUTOIMMUNE DISEASE; CLINICAL MANIFESTATION; CONSENSUS CLUSTERING; GENE INTERACTION NETWORKS; GENE-GENE INTERACTION; GENES EXPRESSION; GENETIC POLYMORPHISMS; GENETIC RISKS; SKIN BIOPSIES; SYSTEM-LEVEL ANALYSIS;

GENE EXPRESSION;

HLA ANTIGEN; INTERFERON; INTERFERON REGULATORY FACTOR 7; NOTCH4 RECEPTOR; STAT4 PROTEIN; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BLK GENE; CELL PROLIFERATION; CLUSTER ANALYSIS; COHORT ANALYSIS; CONSENSUS; CONTROLLED STUDY; CSK GENE; DISEASE COURSE; EXTRACELLULAR MATRIX; FEMALE; FIBROPROLIFERATIVE SPECIFIC GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC DATABASE; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HUMAN GENOME; HUMAN LEUKOCYTE ANTIGEN GENE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INFLAMMATORY GENE; IRAK1 GENE; IRF7 GENE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; NOTCH4 GENE; NUCLEOTIDE SEQUENCE; PLAUR GENE; RISK ASSESSMENT; SKIN FIBROSIS; STAT4 GENE; SYSTEMIC SCLEROSIS; AGED; BIOLOGY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RISK;

AGED; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK; SCLERODERMA, SYSTEMIC; TRANSCRIPTOME;

EID: 84922224910     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004005     Document Type: Article

References (105)

1. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, et al. (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3: e2696.
2. Whitfield ML, George LK, Grant GD, Perou CM, (2006) Common markers of proliferation. Nat Rev Cancer 6: 99–106.
3. Steen VD, Medsger TA, (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66: 940–944.
4. Hinchcliff M, Huang C-C, Wood TA, Matthew Mahoney J, Martyanov V, et al. (2013) Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. J Invest Dermatol: -.
5. Farina G, Lafyatis D, Lemaire R, Lafyatis R, (2010) A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 62: 580–588.
6. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868.
7. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, et al. (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13: 1977–2000.
8. Barabasi AL, (2007) Network medicine—from obesity to the “diseasome”. N Engl J Med 357: 404–407.
9. Barabasi AL, Gulbahce N, Loscalzo J, (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12: 56–68.
10. Langfelder P, Horvath S, (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9: 559.
11. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, et al. (2012) Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 132: 1363–1373.
12. Strehl A, Ghosh J, (2003) Cluster ensembles—a knowledge reuse framework for combining multiple partitions. The Journal of Machine Learning Research 3: 583–617.
13. Monti ST, Pablo; Mesirov, Jill; Golub, Todd (2003) Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine learning 52.
14. Cover TM, Thomas JA (2012) Elements of information theory: Wiley-interscience.
15. Horvath S, Dong J, (2008) Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol 4: e1000117.
16. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, et al. (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100: 12319–12324.
17. Palla G, Derenyi I, Farkas I, Vicsek T, (2005) Uncovering the overlapping community structure of complex networks in nature and society. Nature 435: 814–818.
18. Reimand J, Arak T, Vilo J, (2011) g:Profiler-a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 39: W307–315.
19. Johnson ME, Mahoney JM, Taroni J, Sargent JL, Marmarelis E, et al. (in press) Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS ONE, 10.1371/journal.pone.0114017.
20. Wong AK, Park CY, Greene CS, Bongo LA, Guan Y, et al. (2012) IMP: a multi-species functional genomics portal for integration, visualization and prediction of protein functions and networks. Nucleic Acids Res 40: W484–490.
21. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, et al. (2004) Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138: 540–546.
22. Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, et al. (2003) Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 22: 102–106.
23. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, et al. (2007) Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666–670.
24. Katakura T, Miyazaki M, Kobayashi M, Herndon DN, Suzuki F, (2004) CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 172: 1407–1413.
25. Weis N, Weigert A, von Knethen A, Brune B, (2009) Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants. Mol Biol Cell 20: 1280–1288.
26. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H, (2009) Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 18: 727–729.
27. Gordon S, Martinez FO, (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593–604.
28. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969.
29. Atamas SP, White B, (2003) Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 14: 537–550.
30. Zhou W, Zhang F, Aune TM, (2003) Either IL-2 or IL-12 is sufficient to direct Th1 differentiation by nonobese diabetic T cells. J Immunol 170: 735–740.
31. Gollob JA, Murphy EA, Mahajan S, Schnipper CP, Ritz J, et al. (1998) Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood 91: 1341–1354.
32. Naeger LK, McKinney J, Salvekar A, Hoey T, (1999) Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling. J Biol Chem 274: 1875–1878.
33. O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y, (2011) Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 11: 239–250.
34. Mackay IR, (2009) Clustering and commonalities among autoimmune diseases. J Autoimmun 33: 170–177.
35. de Paus RA, Geilenkirchen MA, van Riet S, van Dissel JT, van de Vosse E, (2013) Differential expression and function of human IL-12Rbeta2 polymorphic variants. Mol Immunol 56: 380–389.
36. Yelo E, Bernardo MV, Gimeno L, Alcaraz-Garcia MJ, Majado MJ, et al. (2008) Dock10, a novel CZH protein selectively induced by interleukin-4 in human B lymphocytes. Mol Immunol 45: 3411–3418.
37. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM, (2005) Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 22: 9–18.
38. Silver K, Bouriez-Jones T, Crockford T, Ferry H, Tang HL, et al. (2006) Spontaneous class switching and B cell hyperactivity increase autoimmunity against intracellular self antigen in Lyn-deficient mice. Eur J Immunol 36: 2920–2927.
39. Hata A, Sabe H, Kurosaki T, Takata M, Hanafusa H, (1994) Functional analysis of Csk in signal transduction through the B-cell antigen receptor. Mol Cell Biol 14: 7306–7313.
40. Manjarrez-Orduno N, Marasco E, Chung SA, Katz MS, Kiridly JF, et al. (2012) CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat Genet 44: 1227–1230.
41. Levinson NM, Seeliger MA, Cole PA, Kuriyan J, (2008) Structural basis for the recognition of c-Src by its inactivator Csk. Cell 134: 124–134.
42. Vang T, Liu WH, Delacroix L, Wu S, Vasile S, et al. (2012) LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 8: 437–446.
43. Fiorillo E, Orru V, Stanford SM, Liu Y, Salek M, et al. (2010) Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue. J Biol Chem 285: 26506–26518.
44. Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP, (2011) Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett 585: 3689–3698.
45. Yamamoto K, Yamaguchi M, Miyasaka N, Miura O, (2003) SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun 310: 1188–1193.
46. Varga J, Whitfield ML, (2009) Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 1: 226–235.
47. Katsumoto TR, Whitfield ML, Connolly MK, (2011) The pathogenesis of systemic sclerosis. Annu Rev Pathol 6: 509–537.
48. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
49. Liu H, Thaker YR, Stagg L, Schneider H, Ladbury JE, et al. (2013) SLP-76 sterile alpha motif (SAM) and individual H5 alpha helix mediate oligomer formation for microclusters and T-cell activation. J Biol Chem 288: 29539–29549.
50. Rege TA, Hagood JS, (2006) Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim Biophys Acta 1763: 991–999.
51. Cohen PY, Breuer R, Wallach-Dayan SB, (2009) Thy1 up-regulates FasL expression in lung myofibroblasts via Src family kinases. Am J Respir Cell Mol Biol 40: 231–238.
52. Phipps RP, Penney DP, Keng P, Quill H, Paxhia A, et al. (1989) Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am J Respir Cell Mol Biol 1: 65–74.
53. Yamamoto A, Ashihara E, Nakagawa Y, Obayashi H, Ohta M, et al. (2011) Allograft inflammatory factor-1 is overexpressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model. Immunol Lett 135: 144–150.
54. Manetti M, Allanore Y, Revillod L, Fatini C, Guiducci S, et al. (2011) A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum 63: 247–256.
55. Saris CG, Horvath S, van Vught PW, van Es MA, Blauw HM, et al. (2009) Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics 10: 405.
56. Farber CR, Bennett BJ, Orozco L, Zou W, Lira A, et al. (2011) Mouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesis. PLoS Genet 7: e1002038.
57. Horvath S, Nazmul-Hossain AN, Pollard RP, Kroese FG, Vissink A, et al. (2012) Systems analysis of primary Sjogren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model. Arthritis Res Ther 14: R238.
58. Lemaire R, Farina G, Kissin E, Shipley JM, Bona C, et al. (2004) Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum 50: 915–926.
59. Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, et al. (2013) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature.
60. Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, et al. (2001) Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 44: 893–901.
61. Tan FK, Tercero GM, Arnett FC, Wang N, Chakraborty R, (2003) Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population. Arthritis Rheum 48: 3295–3296.
62. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, et al. (2003) Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 48: 2585–2592.
63. Alkassab F, Gourh P, Tan FK, McNearney T, Fischbach M, et al. (2007) An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. Rheumatology (Oxford) 46: 1248–1251.
64. Sibinga NE, Feinberg MW, Yang H, Werner F, Jain MK, (2002) Macrophage-restricted and interferon gamma-inducible expression of the allograft inflammatory factor-1 gene requires Pu.1. J Biol Chem 277: 16202–16210.
65. Tian Y, Jain S, Kelemen SE, Autieri MV, (2009) AIF-1 expression regulates endothelial cell activation, signal transduction, and vasculogenesis. Am J Physiol, Cell Physiol 296: C256–266.
66. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, et al. (2012) Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 180: 1080–1094.
67. Mantovani A, Garlanda C, Locati M, (2009) Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 29: 1419–1423.
68. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677–686.
69. Arai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, et al. (2013) Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci 69: 250–258.
70. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, et al. (2009) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284: 34342–34354.
71. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, et al. (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109: 1453–1462.
72. Opitz C, Klein-Weigel PF, Riemekasten G, (2011) Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. VASA 40: 20–30.
73. Arron ST, Dimon MT, Li Z, Johnson ME, T AW, et al. (2014) High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis. J Invest Dermatol 134: 2138–2145.
74. Farina A, Cirone M, York M, Lenna S, Padilla C, et al. (2014) Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol 134: 954–964.
75. Committee. SfSCotARADaTC (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). 23: 581–590.
76. Newman MEJ, (2006) Modularity and community structure in networks. Proceedings of the National Academy of Sciences 103: 8577–8582.
77. Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks.; 2009.
78. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, et al. (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42: 426–429.
79. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, et al. (2011) Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 7: e1002178.
80. Allanore Y, Saad M, Dieude P, Avouac J, Distler JH, et al. (2011) Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 7: e1002091.
81. Martin JE, Broen JC, Carmona FD, Teruel M, Simeon CP, et al. (2012) Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet 21: 2825–2835.
82. Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, et al. (2013) A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet 22: 4021–4029.
83. Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, et al. (2014) Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet 94: 47–61.
84. Rueda B, Gourh P, Broen J, Agarwal SK, Simeon C, et al. (2010) BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 69: 700–705.
85. Gourh P, Agarwal SK, Martin E, Divecha D, Rueda B, et al. (2010) Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 34: 155–162.
86. Manetti M, Allanore Y, Saad M, Fatini C, Cohignac V, et al. (2012) Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Ann Rheum Dis 71: 1034–1041.
87. Koumakis E, Bouaziz M, Dieude P, Ruiz B, Riemekasten G, et al. (2013) A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis. Arthritis Rheum 65: 3202–3208.
88. Dieude P, Guedj M, Truchetet ME, Wipff J, Revillod L, et al. (2011) Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum 63: 1097–1105.
89. Hoshino K, Satoh T, Kawaguchi Y, Kuwana M, (2011) Association of hepatocyte growth factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum 63: 2465–2472.
90. Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, et al. (2013) Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis 72: 1233–1238.
91. Bossini-Castillo L, Martin JE, Broen J, Gorlova O, Simeon CP, et al. (2012) A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 21: 926–933.
92. Dieude P, Bouaziz M, Guedj M, Riemekasten G, Airo P, et al. (2011) Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum 63: 3979–3987.
93. Dieude P, Guedj M, Wipff J, Avouac J, Fajardy I, et al. (2009) Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 60: 225–233.
94. Sharif R, Mayes MD, Tan FK, Gorlova OY, Hummers LK, et al. (2012) IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis 71: 1197–1202.
95. Dieude P, Dawidowicz K, Guedj M, Legrain Y, Wipff J, et al. (2010) Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J Rheumatol 37: 987–992.
96. Carmona FD, Gutala R, Simeon CP, Carreira P, Ortego-Centeno N, et al. (2012) Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 71: 114–119.
97. Carmona FD, Simeon CP, Beretta L, Carreira P, Vonk MC, et al. (2011) Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Ann Rheum Dis 70: 2050–2052.
98. Anaya JM, Kim-Howard X, Prahalad S, Chernavsky A, Canas C, et al. (2012) Evaluation of genetic association between an ITGAM non-synonymous SNP (rs1143679) and multiple autoimmune diseases. Autoimmun Rev 11: 276–280.
99. Coustet B, Agarwal SK, Gourh P, Guedj M, Mayes MD, et al. (2011) Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohorts. J Rheumatol 38: 1033–1038.
100. Wu SP, Leng L, Feng Z, Liu N, Zhao H, et al. (2006) Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 54: 3661–3669.
101. Diaz-Gallo LM, Gourh P, Broen J, Simeon C, Fonollosa V, et al. (2011) Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 70: 454–462.
102. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, et al. (2009) The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 18: 2071–2077.
103. Broen JC, Bossini-Castillo L, van Bon L, Vonk MC, Knaapen H, et al. (2012) A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 64: 264–271.
104. Dieude P, Guedj M, Wipff J, Ruiz B, Riemekasten G, et al. (2010) Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 69: 1958–1964.
105. Gourh P, Arnett FC, Tan FK, Assassi S, Divecha D, et al. (2010) Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 69: 550–555.